Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis.
Cellular immune response
Hemodialysis
Immunoglobulins
Peritoneal dialysis
T cells
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
18
11
2021
revised:
21
02
2022
accepted:
22
02
2022
pubmed:
2
3
2022
medline:
17
3
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
Patients receiving maintenance dialysis (MD) are vulnerable to COVID-19-related morbidity and mortality. Currently, data on SARS-CoV-2-specific cellular and humoral immunity post-vaccination in this population are scarce. We conducted a prospective single-center study exploring the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay [CMIA]) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 MD patients (six with a history of COVID-19). Our results show that MD patients exhibit a high seroconversion rate (91.7%) but the anti-spike IgG antibodies (CMIA) tend to wane rapidly after full immunization. Only 51.7% of the patients developed T cell immune response. High anti-spike IgG antibodies may predict a better cellular immunity. While patients with prior COVID-19 showed the best response after one, SARS-CoV-2-naïve patients may benefit from a third vaccine injection.
Identifiants
pubmed: 35227871
pii: S1521-6616(22)00041-9
doi: 10.1016/j.clim.2022.108961
pmc: PMC8875769
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Messenger
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108961Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34101623
Am J Kidney Dis. 2021 Oct;78(4):571-581
pubmed: 34174364
Nephrol Dial Transplant. 2022 Jan 25;37(2):375-381
pubmed: 34634116
Kidney Int Rep. 2021 Sep;6(9):2292-2304
pubmed: 34250319
JAMA Netw Open. 2021 Sep 1;4(9):e2123622
pubmed: 34473256
J Am Soc Nephrol. 2021 Aug;32(8):1880-1886
pubmed: 34215666
Infection. 2021 Feb;49(1):75-82
pubmed: 32827125
Am J Transplant. 2021 Aug;21(8):2727-2739
pubmed: 34036720
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716
pubmed: 33999200
J Med Virol. 2021 Apr;93(4):2160-2167
pubmed: 33064340
Am J Kidney Dis. 2015 Nov;66(5):884-930
pubmed: 26498416
Clin J Am Soc Nephrol. 2021 Jul;16(7):1073-1082
pubmed: 34031181
Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33
pubmed: 18701615
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
J Am Soc Nephrol. 2021 Oct;32(10):2435-2438
pubmed: 34117129
Kidney Int Rep. 2021 May;6(5):1407-1410
pubmed: 33585728
Lancet Reg Health Eur. 2021 Oct;9:100178
pubmed: 34318288
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Immunity. 2020 Aug 18;53(2):248-263
pubmed: 32717182
Kidney Int. 2021 Jun;99(6):1496-1498
pubmed: 33887318
Kidney Int. 2021 Oct;100(4):928-936
pubmed: 34284044
Clin Kidney J. 2021 Jul 06;14(10):2239-2245
pubmed: 34603701
Kidney Int. 2021 Jun;99(6):1275-1279
pubmed: 33931226
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Kidney Int. 2021 Dec;100(6):1334-1335
pubmed: 34656642
Perit Dial Int. 2011 Mar-Apr;31(2):218-39
pubmed: 21427259
Nephrol Dial Transplant. 2021 Mar 15;:
pubmed: 33720379
Nat Rev Immunol. 2006 May;6(5):417-23
pubmed: 16622477
J Am Soc Nephrol. 2008 Aug;19(8):1483-90
pubmed: 18480314
Nat Rev Nephrol. 2020 Oct;16(10):573-585
pubmed: 32733095
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Kidney Int. 2020 Dec;98(6):1530-1539
pubmed: 32810523